环孢素A联合标准ART治疗原发性HIV-1感染的初步随机临床试验
结果显示联合环孢素A未改善免疫恢复,但环孢素A组非整合DNA在第0至36周显著增加,提示可能存在抗整合效应,值得进一步研究。
要点
- 急性/近期HIV-1感染中,ART联合8周环孢素A未改善免疫恢复。
- 环孢素A组非整合DNA在第0至36周显著增加,提示抗整合效应。
- 两组病毒载量衰减、CD4恢复及整合DNA演变无显著差异。
核心结论
- 急性/近期HIV-1感染中加用环孢素A未改善免疫恢复,但非整合DNA增加提示抗整合效应,值得进一步研究。
研究设计与样本
- ART方案为替诺福韦、恩曲他滨和洛匹那韦/利托那韦。
- 评估0、8和36周病毒载量、免疫应答及整合与非整合DNA病毒储存库。
主要发现
- 估计从HIV-1感染到ART启动的中位时间为63天(IQR 53; 79.5),90%患者处于Fiebig V期。
- 第8周(环孢素A结束)和第36周两组病毒载量衰减、CD4 T细胞恢复、免疫应答标志物及整合DNA演变无显著差异。
- 环孢素A组非整合DNA在第0至36周显著增加。
- 环孢素A耐受良好。
临床怎么用
- 急性/近期HIV-1感染启动ART时加用环孢素A未显示免疫恢复获益,不推荐常规使用。
- 环孢素A对非整合DNA的影响提示抗整合效应,可作为后续研究线索。
局限性
- 原文未报告样本量计算、统计效能及具体P值等局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Initiating ART during acute/recent HIV-1 infection reduces viral reservoir formation. It has been proposed that, during this phase, the size of the viral reservoir could be further reduced by the association of immunomodulatory therapy with ART. Contradictory results have emerged, however, from two trials evaluating the impact on immune recovery and the viral reservoir of adding cyclosporine A to ART during primary HIV-1 infection. PATIENTS AND METHODS: Twenty patients with acute/recent HIV-1 infection were randomized to receive ART alone (tenofovir, emtricitabine and lopinavir/ritonavir) or associated with 8 weeks of cyclosporine A (0.3-0.6 mg/kg twice daily). The impact on viral load, immune response and integrated and non-integrated DNA viral reservoir at 0, 8 and 36 weeks of treatment was evaluated. RESULTS: The estimated median time from HIV-1 infection to ART onset was 63 days (IQR 53; 79.5) with 90% of patients at Fiebig V stage. No significant differences were observed in viral load decay, CD4 T cell recovery, immune response markers or the evolution of integrated DNA at week 8 (end of cyclosporine A) and week 36 between groups. However, non-integrated DNA significantly increased in the cyclosporine A arm between weeks 0 and 36. Cyclosporine A was well tolerated. CONCLUSIONS: Adding cyclosporine A to ART during acute/recent infection did not improve immune recovery. However, unintegrated DNA increased in the cyclosporine A group, suggesting an anti-integration effect, a point warranting further research (ClinicalTrials.gov Identifier: NCT00979706).
引用
- Nicolás D, Ambrosioni J, Sued O, et al. Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial. J Antimicrob Chemother. 2017. PMID: 27999018. doi:10.1093/jac/dkw462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。